Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics' stock has experienced significant growth and volatility. The share price increased by 211.06% over the past year. Recent events impacting the stock include the release of full-year 2025 financial results, participation in healthcare conferences, appointment of a new CFO and board member, presentation of AlloNK cost-effectiveness data, and reports of positive initial safety data from clinical trials. Analyst ratings have varied, with an average rating of "Moderate Buy" and an average price target of $18.67.

There is no information available regarding demand seasonality for Artiva Biotherapeutics' products and services. Demand for its products is likely driven by medical need rather than seasonal patterns.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. Their primary product candidate, AlloNK, is being evaluated in clinical trials for B-cell driven autoimmune diseases, with refractory rheumatoid arthritis as the lead indication. The company's pipeline also includes CAR-NK cell candidates targeting solid and hematologic cancers, such as AB-201 for solid tumors and AB-205 for hematological malignancies.

Artiva Biotherapeutics, Inc. is headquartered in San Diego, California, with R&D and cGMP cell production facilities. The company also utilizes the research and manufacturing capabilities of its partner, GC Cell, in the Republic of Korea. Artiva holds exclusive worldwide rights, excluding Asia, Australia, and New Zealand, to GC Cell's NK cell manufacturing technology and programs.

Artiva Biotherapeutics' brand reputation has been influenced by analyst ratings and clinical trial progress. The company has received a mix of ratings, with an average rating of "Moderate Buy". Key events influencing its reputation include the FDA Fast Track Designation for AlloNK, positive initial safety data for AlloNK in autoimmune diseases, appointment of new leadership, financial results indicating stability, and analyst downgrades introducing some negative sentiment.

Artiva Biotherapeutics, Inc. has a significant number of institutional owners and shareholders. As of April 9, 2026, 36 institutional owners and shareholders held a total of 16,986,122 shares. Major institutional owners include RA Capital Management, L.P., 5AM Venture Management, LLC, and VR Adviser, LLC.